| |
 Shanghai Jinhe Bio-Pharmaceutical Co., Ltd. (Abrr. "Jinhe") , founded in March 2002, is a pharmaceutical enterprise
dedicated to R&D, manufacturing and marketing anti-cancer APIs and their
intermediates. Based on the R&D achievement of Fudan University, we began to
undertake the international business of processing Paclitaxel API. After years
of effort, we successfully developed Paclitaxel, Docetaxel, Irinotecan,
Etoposide etc, from natural extracting anti-cancer products into material source
anti-cancer APIs. In recent years, we developed new APIs, such as Cabazitaxel,
Palonosetron hydrochloride etc. In 2012, we cooperated with Shanghai Zhongxi
Sunve Pharmaceutical Co.,Ltd, (Abrr. "Sunve") became a member of Shanghai
Pharmaceuticals Holding Co.,Ltd. (Abrr. "SPH"). Since then, we targeted
ourselves as the production base of SPH on oncology products. In 2015, we and
Shanghai Huayu Chinese Herbs Co., Ltd. (Abrr. "Huayu") both subsidiaries of SPH,
reorganized Dali Zhonggu Yew Biological Co., Ltd. (Abrr. "Zhonggu Biological")
by way of investment in cash. This move indicates that SPH will further
integrate its oncology drug industry chain and build its advantage in APIs. In
January 2017, we achieved GMP certificate on Bulk Drug (Paclitaxel, Docetaxel).
We are always committed to be a competitive and responsible company in global
pharmaceutical industry.
|
| |
|
|
